Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in Type 2 diabetes mellitus
| Autor: | I C Smith, Barrie Chubb, William J. Valentine, Melanie J. Davies |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Cost effectiveness Cost-Benefit Analysis Endocrinology Diabetes and Metabolism Type 2 diabetes Body Mass Index Sitagliptin Phosphate Young Adult Endocrinology Glucagon-Like Peptide 1 Internal medicine Diabetes mellitus Internal Medicine Humans Hypoglycemic Agents Medicine UK cost-effectiveness Aged Aged 80 and over liraglutide business.industry Liraglutide Original Articles Middle Aged Triazoles medicine.disease Metformin United Kingdom Glimepiride Sulfonylurea Compounds Treatment Outcome Diabetes Mellitus Type 2 Pyrazines Sitagliptin Female Quality-Adjusted Life Years business medicine.drug |
| Zdroj: | Diabetic Medicine |
| ISSN: | 1464-5491 0742-3071 |
| DOI: | 10.1111/j.1464-5491.2011.03429.x |
| Popis: | Diabet. Med. 29, 313–320 (2012) Abstract Aim To investigate the cost-effectiveness of liraglutide as add-on to metformin vs. glimepiride or sitagliptin in patients with Type 2 diabetes uncontrolled with first-line metformin. Methods Data were sourced from a clinical trial comparing liraglutide vs. glimepiride, both in combination with metformin, and a clinical trial comparing liraglutide vs. sitagliptin, both as add-on to metformin. Only the subgroup of patients in whom liraglutide was added to metformin monotherapy was included in the cost–utility analysis. The CORE Diabetes Model was used to simulate outcomes and costs with liraglutide 1.2 and 1.8 mg vs. glimepiride and vs. sitagliptin over patients’ lifetimes. Treatment effects were taken directly from the trials. Costs and outcomes were discounted at 3.5% per annum and costs were accounted from a third-party payer (UK National Health System) perspective. Results Treatment with liraglutide 1.2 and 1.8 mg resulted, respectively, in mean increases in quality-adjusted life expectancy of 0.32 ± 0.15 and 0.28 ± 0.14 quality-adjusted life years vs. glimepiride, and 0.19 ± 0.15 and 0.31 ± 0.15 quality-adjusted life years vs. sitagliptin, and was associated with higher costs of £3003 ± £678 and £4688 ± £639 vs. glimepiride, and £1842 ± £751 and £3224 ± £683 vs. sitagliptin, over a patient’s lifetime. Both liraglutide doses were cost-effective, with incremental cost-effectiveness ratios of £9449 and £16 501 per quality-adjusted life year gained vs. glimepiride, and £9851 and £10 465 per quality-adjusted life year gained vs. sitagliptin, respectively. Conclusions Liraglutide, added to metformin monotherapy, is a cost-effective option for the treatment of Type 2 diabetes in a UK setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text